Prosecutors allege allografts were applied inappropriately, not applied, or ordered for terminal patients
WASHINGTON, DC, August 26, 2026 — Federal prosecutors have outlined three sharply different forms of alleged misconduct behind Leigh Tesar’s disputed wound-care billing: allografts purportedly used in medically inappropriate circumstances, applications allegedly billed but never performed, and expensive treatment directed toward terminally ill patients whose wounds supposedly could not heal.
The distinctions are central to understanding the federal case, because a disputed clinical decision, a service that allegedly never occurred, and treatment provided to a patient with limited restoration potential each require different evidence, expert analysis, and proof of criminal intent.
In its official announcement describing the Leigh Tesar prosecution, the United States Attorney’s Office for the Middle District of Florida said Medicare received more than $118 million in claims and paid approximately $61 million during an alleged eighteen-month operation.
The June indictment charges Tesar, a Sarasota nurse practitioner, alongside registered nurses Walter Presha Junior and Koby Evans, while alleging that patient referrals, costly allografts, false medical records, improper inducements, and concealed kickbacks formed interconnected parts of the reimbursement structure.
All allegations remain unproven, and the indictment represents the government’s accusation rather than a judicial finding, meaning Tesar, Presha, and Evans retain the presumption of innocence unless prosecutors later establish guilt through valid pleas or verdicts.
The government separated several billing theories
The United States Attorney’s Office summarized the case by saying certain allografts were never applied, others were placed on infected wounds, and still others were used on wounds prosecutors contend could not heal because the patients were terminally ill.
The underlying indictment provides a wider list, alleging applications without attempted or confirmed conservative treatment, continued use after wounds stopped responding, treatment despite active infection, product choices supposedly driven by profit, and claims for applications never rendered.
Those categories should not be collapsed into a single vague accusation of unnecessary care, because prosecutors must connect particular claims with particular patients, records, clinical conditions, products, service dates, payment decisions, and knowingly false representations.
A nonresponsive wound raises a medical-necessity question, an infected wound raises a coverage and clinical-timing question, and a nonexistent application raises a factual-performance question that may depend less heavily on competing professional judgment.
The government also alleges that kickbacks rendered additional claims ineligible for reimbursement, creating another theory under which treatment could have physically occurred yet still produce criminal exposure if prosecutors prove prohibited remuneration caused federally funded referrals or purchasing decisions.
“Skin graft” is accessible but medically imprecise
The phrase “skin graft billing fraud” makes the accusation understandable to a general audience, although the charging document more precisely describes bioengineered skin substitutes, including some amniotic membrane allografts made from human placental tissue and applied over open wounds.
These products are intended to assist wound closure or skin growth in appropriate circumstances, but Medicare reimbursement depends upon coverage requirements addressing medical necessity, documentation, prior treatment, the patient’s condition, and whether the product and associated service were delivered as represented.
Traditional grafting can suggest transplantation of a patient’s own skin or donor skin, whereas the products described here belong to a specialized wound-care market whose coding, pricing, square-centimeter units, repeated applications, and contractor policies create unusually complicated billing records.
That complexity can produce legitimate disagreements involving wound measurements, product selection, discarded material, treatment intervals, documentation timing, or clinical response, yet prosecutors contend the Tesar claims crossed beyond ordinary disagreement into deliberate deception and unlawful financial arrangements.
The terminology matters for search accuracy and public understanding, because readers encountering “skin graft” should recognize that the federal allegations concern reimbursed wound allografts and related application services, rather than every surgical grafting procedure performed within conventional hospital medicine.
Medicare coverage depended upon documented improvement
According to the indictment, Medicare Part B covered qualifying items and services furnished by physicians, nurse practitioners, group practices, and other enrolled providers when those services were medically reasonable, medically necessary, accurately documented, and actually supplied as represented.
First Coast Service Options administered relevant Florida claims as Medicare’s contractor, while local coverage determinations cited by prosecutors required continuing wound care to correspond with documented improvement, accepted treatment standards, contributing conditions, and the patient’s expected restoration potential.
For diabetic foot ulcers and venous leg ulcers, the cited policy generally required at least four weeks of completed and documented conservative care before covered skin-substitute treatment, including measures involving debridement, pressure relief, infection control, and drainage management.
The record was also expected to identify why those earlier measures failed, while policy language described in the indictment discouraged switching products during a twelve-week treatment course and considered repeat applications unreasonable when a previous application had been unsuccessful.
These checkpoints gave investigators measurable questions for each claim: what treatment preceded the allograft, where that treatment was documented, whether the wound improved, which underlying conditions remained uncontrolled, and what clinical reasoning supported continuation or product selection.
The defense can answer those questions with contemporaneous charts, photographs, caregiver observations, prior-provider records, expert testimony, and explanations of unusual clinical circumstances, while prosecutors must show that any deficient documentation reflected knowing fraud rather than incomplete administration or disputed medicine.
Conservative treatment became a factual dividing line
Prosecutors allege that allografts were sometimes applied without attempting, completing, or confirming earlier conservative care, a contention that directly challenges whether the advanced products became eligible under the coverage criteria incorporated into the federal charging theory.
Conservative care is not merely a waiting period, because wound records may need to describe cleansing, debridement, pressure redistribution, infection management, vascular assessment, dressings, drainage control, glucose management, nutrition, and other interventions tailored to the beneficiary’s condition.
If records genuinely show four weeks of unsuccessful treatment and a reasoned transition toward an allograft, the defense may argue that the government has mistaken aggressive care for fraudulent care or interpreted imperfect notes more rigidly than treating clinicians did.
If investigators instead prove that earlier treatment was invented, backdated, copied, or attributed to Tesar when another provider never delivered it, the missing prerequisite could support both a coverage theory and an inference that participants understood the obstacle.
The indictment specifically alleges false statements claiming that certain treatments occurred when none were rendered, that Tesar personally administered earlier conservative care, and that wounds had been documented by a medical provider on dates preceding the actual records.
Electronic metadata, signature histories, image timestamps, template reuse, user-access logs, product orders, and claim-submission dates could therefore become decisive evidence when jurors determine whether documentation evolved normally or was manufactured to satisfy reimbursement requirements.
Infected wounds created another coverage concern
The government alleges that some allografts were applied to infected wounds, while the cited contractor policy described active infection and inadequately controlled underlying conditions as circumstances that could make skin-substitute applications ineligible for coverage involving specified ulcer categories.
That allegation does not mean an infected wound should receive no care, because infection can require urgent assessment, antibiotics, drainage, debridement, pressure management, dressings, pain relief, and other interventions independent of whether a costly allograft is appropriate at that moment.
At trial, experts may examine cultures, antibiotics, temperature, drainage, odor, tissue appearance, laboratory results, vascular status, photographs, and clinical notes to determine whether an active infection existed and whether it should have delayed the disputed product.
Timing may be especially important because a wound can move between infected and controlled states, meaning the government must connect the asserted coverage barrier to the precise application date rather than relying on an infection documented substantially earlier or later.
Defense lawyers can also challenge whether the applicable policy covered the particular wound type, whether available evidence actually established active infection, and whether a reasonable clinician could conclude that underlying factors were sufficiently controlled before proceeding.
The prosecution, however, may argue that repeated applications despite documented infection show more than a close medical judgment, especially if communications, purchasing records, or compensation calculations suggest reimbursement value outweighed recorded clinical warnings.
Continued applications allegedly ignored nonresponse
Another prosecution theory concerns allografts purportedly applied after wounds clearly failed to respond, a circumstance that could undermine ongoing medical necessity when the relevant coverage framework expected improvement and disfavored repetition following an unsuccessful application.
Wound healing rarely follows a perfectly linear course, so jurors may hear competing interpretations of changes in dimensions, depth, tissue quality, drainage, pain, infection, perfusion, and photographs across visits rather than receiving one obvious measurement.
Prosecutors can strengthen their position by identifying consistent deterioration, unchanged measurements, repeated product use, absent clinical rationale, or records falsely describing progress, while the defense can emphasize temporary setbacks, measurement variability, and reasonable efforts to preserve tissue.
The product sequence may also matter because the indictment alleges that allografts were selected solely to maximize profit, and separately cites communications comparing products priced at approximately $1,591 and $2,000 per square centimeter.
Price alone does not prove improper medicine, since clinicians and suppliers routinely consider product availability, characteristics, anticipated performance, acquisition terms, and reimbursement, but a financial motive can become probative when connected with unnecessary switching or continued nonresponsive treatment.
Investigators will likely compare each treatment decision with claim amounts, invoices, distributor communications, referral assignments, and payment calculations, seeking a chronological pattern in which worsening clinical evidence coincided with persistent or increasingly expensive billing.
Terminal illness does not eliminate legitimate wound care
The allegation involving terminally ill patients is especially sensitive because people approaching the end of life can still require skilled wound management for pain, odor, drainage, bleeding, infection, pressure injury, cleanliness, mobility, comfort, and personal dignity.
Accordingly, neither terminal illness nor hospice participation automatically establishes that every wound-care service was unnecessary, and responsible reporting should avoid implying that seriously ill beneficiaries were undeserving of treatment simply because complete healing appeared unlikely.
The indictment advances a narrower contention: prosecutors say expensive allografts were applied to wounds that would not heal because a patient was terminally ill, challenging whether those products served the restorative purpose represented to Medicare under the cited coverage standard.
The key evidence may include prognosis, hospice records, comorbidities, circulation, nutrition, mobility, life expectancy, wound trajectory, treatment goals, family discussions, and whether clinicians documented comfort-focused objectives rather than realistic expectations of durable closure.
Defense experts may argue that prognosis is uncertain, partial closure can still reduce suffering, or a treatment offered reasonable clinical benefit despite limited life expectancy, while government experts may contend the product could not achieve its billed therapeutic purpose.
Patient consent and cost explanations may also face scrutiny, because prosecutors separately allege that beneficiaries were encouraged to begin or continue treatment through misrepresented expenses, waived copayments, free supplies, jewelry, and a leather recliner.
Beneficiaries should not be treated as knowing participants merely because they accepted care or gifts, since the charging narrative primarily portrays them as patients whose wounds, Medicare eligibility, dependency, and clinical vulnerability allegedly created opportunities for others.
Claims for applications never rendered present a different dispute
The allegation that some allograft applications never occurred is conceptually different from a disagreement over necessity, because the government would be asserting that Medicare paid for a represented service without the underlying clinical event happening as claimed.
Investigators can test that assertion by reconciling product shipments, inventory, lot numbers, purchase invoices, delivery locations, treatment schedules, staff assignments, medical photographs, packaging, waste records, beneficiary accounts, and electronic entries surrounding each billed date.
A large mismatch between products acquired and units billed could support suspicion, although investigators would still need to consider timing differences, transferred inventory, discarded material, canceled visits, missing supplier records, and legitimate documentation errors before attributing criminal intent.
Patient or caregiver testimony may offer direct evidence, but memory can be imperfect when treatments occurred repeatedly, wounds were covered, beneficiaries were seriously ill, several clinicians visited, or the product’s appearance was unfamiliar to nonmedical observers.
Photographs and metadata can provide more objective anchors, yet the defense may dispute whether images correspond to the charged date, patient, wound, product, or application, requiring careful authentication rather than assumptions based on file names alone.
Because non-performance is generally more binary than medical necessity, a proven nonexistent service could become a powerful trial fact, but it cannot automatically establish that every other claim, treatment decision, or defendant participated in the same conduct.
Payment records reveal scale but not guilt
The indictment alleges that Tesar and Primecare received more than $61 million from Medicare after submitting over $118 million in disputed claims between approximately May 2024 and November 2025, producing an overall payment ratio near fifty-two percent.
That difference of roughly $57 million should not automatically be described as fraud prevented, because unpaid claims can reflect denials, edits, pending review, corrected submissions, coverage limits, abandoned requests, timing, or reasons not disclosed within the public charging record.
Five substantive health-care fraud counts identify approximately $3.96 million billed for five anonymized beneficiaries and approximately $2.82 million paid, giving prosecutors selected transactions to organize patient-specific testimony, records, products, and expert conclusions.
The selected executions produced a payment ratio near seventy-one percent, higher than the scheme-wide rounded ratio, although five charged examples cannot reliably establish the composition, legitimacy, or payment history of the much larger universe prosecutors allege.
Medicare payment is not a final clinical endorsement, because claims can be processed from coded representations before later audits compare them with charts, images, product records, beneficiary histories, referral relationships, and financial transfers unavailable during initial adjudication.
Likewise, a paid claim does not prove fraud simply because prosecutors later challenge it, and the government must establish falsity, materiality, causation, knowledge, and the required intent rather than inviting jurors to infer criminal conduct from large numbers alone.
The records case may connect medicine with money
Prosecutors allege that Tesar and others falsified patient charts to make allograft use appear medically necessary and compliant, potentially bridging disputed bedside decisions with representations that caused Medicare to release federal funds.
The indictment also alleges that following a Medicare audit, Tesar removed her name as Primecare’s owner from Florida corporate records while retaining ownership and managerial control, supposedly seeking to reduce scrutiny over continued claim submissions.
An ownership amendment does not independently prove earlier billing fraud, and the defense may offer administrative, licensing, tax, financing, or business explanations while challenging whether the change concealed information that Medicare actually requested or relied upon.
Prosecutors may nevertheless emphasize timing, practical control, bank authority, employee instructions, system credentials, contracts, distributions, communications, and audit responses when arguing that formal filings did not accurately reflect who continued directing Primecare’s operations.
The audit itself can establish a chronology of notice, showing which records reviewers requested, what deficiencies they identified, how the practice answered, whether documentation changed afterward, and whether challenged billing continued after coverage concerns became explicit.
That chronology could help distinguish an earlier misunderstanding from later willfulness, although every inference must be tested against admissibility rules, complete communications, legitimate corrective efforts, and proof connecting individual defendants with specific changes or submissions.
Kickback allegations supply a parallel route to ineligibility
The indictment alleges that Presha and Evans entered into purported sales arrangements with an unnamed Pennsylvania distributor while actually referring Medicare beneficiaries to Tesar, with compensation allegedly connected to the invoiced value of products used for those patients.
On August 15, 2025, the distributor allegedly deposited approximately $397,570 into an account associated with Presha and approximately $10,998 into an account associated with Evans, transactions underlying four substantive kickback counts involving payment and receipt.
Those allegations matter to the treatment claims because Medicare conditions reimbursement upon compliance with federal anti-kickback requirements, allowing prosecutors to argue that an otherwise delivered product became ineligible when purchased, furnished, or referred through prohibited remuneration.
The defense can seek evidence of genuine sales, education, inventory support, marketing, account development, expenses, fair-market compensation, and independent clinical decisions, while contesting whether prosecutors have proven that either payment knowingly rewarded federally reimbursable referrals.
Tesar faces five health-care fraud counts, one conspiracy count, and two payment counts, while Presha and Evans face the conspiracy count and one receipt count each, requiring jurors to assess each defendant and statutory theory separately.
Evidence suggesting that one allograft was unnecessary cannot replace proof that Presha or Evans understood a referral arrangement to be unlawful, just as evidence of a payment cannot establish automatically that Tesar fabricated a particular patient record.
Public reporting condensed a complicated indictment
Local reporting on the Sarasota wound-care charges summarized the government’s central figures and treatment allegations, illustrating how a twenty-one-page indictment quickly became a concise public narrative about $118 million billed, $61 million paid, and vulnerable patients.
That compression is understandable, but phrases such as “fraudulent grafts” can blur whether prosecutors allege a product was unnecessary, ineligible, never furnished, tainted by kickbacks, supported by false documentation, or applied under clinical conditions that defeated coverage.
Precise attribution protects both accuracy and public confidence, because the current record contains detailed grand jury allegations but has not yet undergone public cross-examination, competing expert testimony, defense presentation, final evidentiary rulings, judicial instructions, or jury deliberation.
Coverage should also avoid converting the government’s approximately $11.8 million in seized assets into a final recovery, since seizure preserves disputed property while defendants and qualifying third parties may contest ownership, tracing, valuation, commingling, and forfeiture.
The indictment seeks approximately $61.63 million from Tesar, approximately $3.19 million from Presha, and approximately $263,223 from Evans, but those figures remain allegations concerning proceeds rather than final judgments, restitution orders, or established personal profits.
Responsible updates should identify later dismissals, pleas, acquittals, convictions, sentences, restitution decisions, or forfeiture rulings with the same prominence given to the original accusations, especially when search results can preserve an incomplete procedural snapshot indefinitely.
The national takedown widened the enforcement context
Federal officials announced the Tesar case during the 2026 National Health Care Fraud Takedown, which involved charges against 455 defendants across fifty-six federal districts and forty-five states and territories in alleged schemes totaling more than $6.5 billion in claims.
Authorities said ninety physicians and other licensed professionals were included, and more than $182 million in assets were seized nationally, figures that explain the operation’s scale without providing evidence that establishes any allegation against the three Florida defendants.
Wound allograft billing is particularly suitable for data analysis because investigators can compare provider totals, product prices, square-centimeter units, repeat applications, treatment duration, patient concentration, referral sources, claim outcomes, and payment destinations across standardized records.
An extreme outlier can identify where investigators should look, but statistics cannot decide whether a particular wound required treatment, whether an application occurred, whether documentation was knowingly false, or whether compensation represented a prohibited referral payment.
The strongest case will therefore depend upon convergence among data, medical records, product movement, electronic communications, bank transfers, corporate filings, patient evidence, employee testimony, and experts capable of explaining both coverage rules and real-world wound care.
The defense can fracture that convergence by demonstrating legitimate services, incomplete context, uncertain attribution, reasonable clinical judgment, inconsistent memories, faulty assumptions, or aggregation methods that improperly treat every paid claim as equivalent conduct.
Reputational consequences arrive before adjudication
Allegations involving terminal patients and nonexistent treatment can create exceptional reputational damage because they combine taxpayer loss with perceived exploitation of vulnerable people, even though emotionally powerful accusations remain subject to the same evidentiary burdens as every federal charge.
Health-care organizations confronting comparable scrutiny may require disciplined crisis public relations management that preserves records, coordinates verified statements with counsel, corrects demonstrable inaccuracies, respects court restrictions, and avoids claiming either guilt or vindication before the evidence is adjudicated.
Longer-term reputation rebuilding strategies can communicate documented compliance reforms, accurate procedural developments, verified credentials, and meaningful accountability without erasing legitimate reporting, manipulating public records, intimidating critics, or concealing information important to patients and regulators.
Nothing in the reviewed public materials indicates that Amicus International Consulting represents Tesar, Presha, Evans, Primecare, the unnamed distributor, or any connected organization, and these observations address only general communication pressures surrounding unresolved public accusations.
For clinicians and compliance leaders, the practical lessons include documenting conservative care, separating referral compensation from treatment decisions, reconciling inventory with claims, recording infection status, reassessing nonresponsive wounds, and clarifying restorative versus palliative goals for terminally ill patients.
For journalists and readers, the essential discipline is equally clear: distinguish care alleged to be inappropriate from care alleged never to have occurred, preserve the special nuance surrounding terminal illness, and attribute every unresolved contention to prosecutors.
What prosecutors must ultimately establish
To prove the health-care fraud counts, the government must do more than show that Medicare paid large claims or that experts now disagree with treatment, because prosecutors must establish a knowing and willful scheme involving materially false representations connected with federal money.
To prove the kickback charges, prosecutors must establish the required knowing and willful exchange involving remuneration and federally reimbursable referrals, while the defense can challenge purpose, payment characterization, commercial substance, individual knowledge, and the independence of clinical decisions.
Patient-specific proof will remain indispensable, since aggregate totals cannot reveal whether conservative care occurred, an infection remained active, a wound stopped responding, a terminal prognosis foreclosed healing, or an identified allograft application actually happened.
The government’s public summary gives the Leigh Tesar skin graft billing case a strong outline, but the coming litigation must provide the detailed clinical, financial, and testimonial evidence needed to turn that outline into admissible proof.
Until that process concludes, the approximately $118 million billed, $61 million paid, and $11.8 million seized remain components of a contested prosecution whose most serious treatment allegations have not been established in court.